BrainXell provides a range of high-purity, iPSC-derived human neurons for research and development with a focus on drug discovery.
BrainXell has raised $13.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2021.
BrainXell is headquartered in Madison, United States.
BrainXell provides a range of high-purity, iPSC-derived human neurons for research and development with a focus on drug discovery.
BrainXell is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BrainXell — Funding & Investors." VCBacked, September 13, 2021, https://www.vcbacked.co/company/brainxell. Accessed August 13, 2026.
VCBacked. (2021). BrainXell — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/brainxell
{{cite web |title=BrainXell — Funding & Investors |url=https://www.vcbacked.co/company/brainxell |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated